Skip Navigation


European Heart Journal Advance Access originally published online on August 2, 2007
European Heart Journal 2007 28(18):2183-2184; doi:10.1093/eurheartj/ehm326
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/18/2183    most recent
ehm326v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Serebruany, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Serebruany, V. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Aggressive antiplatelet strategies: time to reconsider?

Victor L. Serebruany*

HeartDrugTM Research Laboratories, Johns Hopkins University, Osler Medical Building, 7600 Osler Drive, Suite 307, Towson, MD 21204, USA

* Tel: +1 410 203 1665; fax: +1 410 601 9061. E-mail address: heartdrug@aol.com

This editorial refers to ‘An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial’ by T.H. Wang et al., on page 2200

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

The landmark second analysis of the CHARISMA trial strongly suggests that dual therapy with clopidogrel and aspirin in asymptomatic patients is associated with excess cardiovascular mortality when compared with those patients treated with aspirin alone.1 Indeed, based on the data from 3284 primary prevention patients, there was a highly significant (P = 0.001) increase . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
Thomas H. Wang, Deepak L. Bhatt, Keith A.A. Fox, Steven R. Steinhubl, Danielle M. Brennan, Werner Hacke, Koon-Hou Mak, Thomas A. Pearson, William E. Boden, P. Gabriel Steg, Marcus D. Flather, Gilles Montalescot, Eric J. Topol, and on behalf of the CHARISMA Investigators
EHJ 2007 28: 2200-2207. [Abstract] [Full Text]